The clinical backbone of thyroid cancer management remains radioiodine imaging and therapy, which exploits the unique ability of well-differentiated thyroid cells to concentrate iodine. When radioiodine is taken up by thyroid tissue or metastases, physicians can both locate disease and deliver targeted radiation with remarkable precision. However, the review emphasizes that this elegant system has a critical weakness: heterogeneity of iodine uptake. As tumors dedifferentiate and become more aggressive, they progressively lose the molecular machinery needed to transport iodine, rendering radioiodine therapy ineffective in refractory cases. This loss of uptake is one of the strongest predictors of poor outcome in differentiated thyroid cancer, and it has long frustrated clinicians who watch a treatable disease turn lethal.

To address this gap, the authors highlight a wave of technical advances in imaging that are improving diagnostic accuracy and therapeutic decision-making. Dosimetry-guided radioiodine therapy, which calculates the actual radiation dose delivered to tumors and organs at risk rather than relying on fixed administered activities, allows safer and more effective treatment individualization. Hybrid imaging modalities that fuse functional and anatomical information, including SPECT/CT, PET/CT, and PET/MRI, provide sharper localization of disease and better characterization of lesions that traditional scans may miss. Novel radiotracers such as fluorodeoxyglucose, the workhorse of oncological PET imaging, and sodium fluoride, which maps bone turnover, extend the diagnostic toolkit, particularly for aggressive tumors that no longer concentrate iodine.

While imaging reveals where disease is and how it behaves, genomics explains why. The review details how genomic profiling has reshaped the classification, prognosis, and therapy selection of thyroid cancer by identifying key driver alterations. In papillary thyroid carcinoma, the most common form of the disease, mutations in BRAF, particularly the V600E variant, and rearrangements of RET/PTC dominate the landscape. Follicular thyroid carcinoma more often harbors RAS mutations or the PAX8/PPARγ rearrangement. More ominous alterations, including TERT promoter mutations and TP53 inactivation, mark tumors with aggressive behavior and are frequently found in poorly differentiated and anaplastic thyroid carcinoma, the most lethal form of the disease. Fusions involving ALK and NTRK add further therapeutic targets to the map.

The clinical payoff of this genetic knowledge is already tangible. Targeted inhibitors against BRAF, RET, and NTRK have demonstrated clinical benefit in patients whose tumors carry the corresponding alterations, offering options beyond chemotherapy for advanced disease. The review also underscores the importance of synergistic mutations, where combinations of alterations produce more aggressive behavior than either alone. The pairing of BRAF V600E with TERT promoter mutations is the classic example, a combination associated with high recurrence risk, distant metastasis, and mortality. Recognizing such interactions, the authors argue, may support the investigation of combination treatment strategies that attack multiple vulnerabilities simultaneously rather than relying on single-agent approaches.

Layered on top of imaging and genomics is a third pillar: bioinformatics and multi-omics analysis. The review describes how recent studies have used high-throughput mutation mapping, pathway analysis, and biomarker discovery to make sense of the enormous datasets generated by modern sequencing. Drawing on patient genomic data from The Cancer Genome Atlas and the cBioPortal platform, researchers have applied visualization and data-wrangling tools in the R programming environment, including packages such as ggplot2, dplyr, ggrepel, and tidyr, to organize and interpret mutation patterns across hundreds of tumors. This computational infrastructure turns raw sequencing output into biologically meaningful insight at a scale impossible for manual analysis.

The pathway analyses reviewed in the paper, conducted using Gene Ontology, KEGG, and Reactome databases, revealed that thyroid cancer is deeply entangled with processes beyond simple growth signaling. Altered tumors show involvement of extracellular matrix organization, cell junction assembly, PI3K-Akt signaling, and collagen formation. These findings matter because they point to the microenvironmental and structural remodeling that accompanies malignant progression, and they suggest potential vulnerabilities that extend beyond the canonical MAPK pathway that has dominated thyroid cancer drug development. Understanding these broader pathway networks may help explain why some tumors metastasize aggressively while others remain indolent for decades.

The central thesis of the review is that no single technology is sufficient on its own. Integrating insights from molecular imaging, genomics, and computational biology enhances understanding of tumor biology, supports risk stratification, and informs the design of personalized therapies. In practice, this means a patient with a newly diagnosed thyroid nodule might undergo genomic testing of biopsy material to identify driver mutations, followed by tailored imaging to map the extent and metabolic activity of disease. A tumor with a RET fusion would point toward RET inhibitors; evidence of iodine-avid metastases on dosimetry scans would support radioiodine; a BRAF and TERT combination would flag high risk and justify closer surveillance and combination approaches.

Looking forward, the authors identify machine learning-driven data integration as a key future direction. Algorithms capable of fusing imaging features, genomic profiles, and clinical outcomes could improve patient stratification beyond what either data type achieves alone, potentially predicting which tumors will dedifferentiate before they do so. The expanded clinical application of next-generation sequencing and hybrid imaging is likewise expected to improve patient management, bringing technologies that are currently concentrated in specialized centers into broader routine use. Challenges remain, including the interpretation of variants of uncertain significance and the cost of comprehensive profiling, but the trajectory is clear.

For a disease diagnosed in hundreds of thousands of people worldwide each year, the convergence described in this review represents more than an academic exercise. It signals a shift from a one-size-fits-all paradigm, in which nearly every patient received surgery and radioiodine regardless of tumor biology, toward a framework in which the molecular identity of each cancer dictates both how it is imaged and how it is treated. As the authors conclude, the synergy of molecular imaging and genomics is redefining what precision oncology means for thyroid cancer, offering hope that even the most refractory tumors will eventually meet their match.

Subject of Research: Integration of molecular imaging and genomics for personalized thyroid cancer management

Article Title: Synergistic role of molecular imaging and genomics in thyroid cancer management: from diagnosis to personalized treatment

Article References: Ahmadi, S., Hoseini, M., Ravari, M. S., Zarei, M., Shahrokhi, P., & Mousavi, P. (2026). Synergistic role of molecular imaging and genomics in thyroid cancer management: from diagnosis to personalized treatment. Journal of Translational Medicine, 24(1), Article 1214. https://doi.org/10.1186/s12967-026-08839-y

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08839-y

Keywords: thyroid cancer, molecular imaging, genomics, radioiodine therapy, BRAF V600E, TERT promoter, PET/CT, SPECT/CT, targeted therapy, bioinformatics, TCGA, precision oncology

Hepatocellular carcinoma, or HCC, is one of the leading causes of cancer-related death worldwide, and its molecular landscape has been mapped in increasing detail over the past decade through large-scale sequencing efforts. Among the recurrent alterations identified in human HCC samples, mutations in CTNNB1 and in the TERT promoter stand out for their exceptionally high frequency. CTNNB1 mutations stabilize the β-catenin protein, allowing it to escape degradation, accumulate in the cell nucleus and drive the expression of proliferation-promoting genes. TERT promoter mutations, meanwhile, create binding sites for transcription factors that boost expression of telomerase reverse transcriptase, the enzyme that rebuilds chromosome ends and grants cells the replicative immortality that cancer demands. Despite the well-documented prevalence of both alterations, the functional consequences of their co-occurrence had remained poorly understood, leaving a significant gap in the mechanistic picture of how liver tumors arise.

To begin closing that gap, the research team first turned to publicly available data from The Cancer Genome Atlas, or TCGA, a comprehensive genomic database of human tumors. Their statistical analysis of HCC samples revealed a significant association between mutations in CTNNB1 and mutations in the TERT promoter, with a Fisher’s exact test yielding a P value below 0.01. In practical terms, this means that liver tumors carrying one of these alterations are significantly more likely than chance alone would predict to carry the other as well. Such non-random co-occurrence is a classic signature of cooperating cancer genes: when two alterations appear together more often than expected, it typically suggests that their combined effect confers a selective growth advantage that natural selection within the tumor favors strongly.

Association, however, is not causation. To test whether β-catenin and TERT genuinely cooperate in driving liver cancer, the researchers employed an elegant and rapid animal modeling technique known as hydrodynamic tail vein injection, or HTVI. This method involves injecting plasmid DNA into the bloodstream of mice in a way that delivers the genetic material directly into hepatocytes, the main functional cells of the liver, allowing researchers to express specific oncogenes in liver tissue and monitor tumor development over time. The team constructed plasmids encoding a constitutively active form of β-catenin, called Δ90 β-catenin, which carries a deletion that prevents its degradation, alongside plasmids encoding TERT itself.

The results of these experiments were striking. When Δ90 β-catenin and TERT were coexpressed in mouse livers, the animals developed hepatocellular carcinoma rapidly, with tumors emerging far sooner and more abundantly than in any of the control conditions. In contrast, expression of Δ90 β-catenin alone produced only minimal tumor formation, and expression of TERT alone produced essentially no tumors at all. This pattern is the hallmark of oncogenic synergy: neither alteration is sufficient on its own to transform liver tissue, but together they unleash a potent cancer-driving program. The finding provides a functional explanation for the genetic co-occurrence observed in human patient data, and it suggests that the two mutations are not merely passengers traveling together but active collaborators in hepatocarcinogenesis.

With the synergy established, the researchers turned their attention to the molecular mechanism underlying it. Using immunohistochemistry, a technique that detects specific proteins in tissue sections, they examined the tumors induced by combined β-catenin and TERT expression and looked for signs of activated signaling cascades. What they found was strong phosphorylation of ERK1/2, the terminal kinases of the MAPK/ERK pathway, a central signaling cascade that transmits growth-promoting signals from the cell surface to the nucleus. ERK1/2 phosphorylation is a well-established readout of MAPK/ERK pathway activation, and its robust presence in the β-catenin and TERT-driven tumors indicated that this pathway had been switched on in the tumor cells.

To determine whether this pathway activation was merely a byproduct of tumorigenesis or an essential driver of it, the researchers performed a genetic knockdown experiment targeting MEK1/2, the upstream kinases responsible for phosphorylating ERK1/2. When MEK1/2 expression was suppressed in the mouse livers receiving the β-catenin and TERT plasmids, tumor formation was markedly reduced. This loss-of-function experiment confirmed that MAPK/ERK signaling is not incidental but indispensable for the oncogenic cooperation between β-catenin and TERT. In other words, without the MAPK/ERK cascade, the two cancer genes lose their combined power to transform liver tissue, identifying the pathway as a critical dependency of this tumor subtype.

The clinical implications of these findings are considerable. The MAPK/ERK pathway is already a major focus of drug development across many cancer types, and a range of inhibitors targeting components of the cascade, including MEK inhibitors, have been developed and tested clinically. The new study suggests that patients whose liver tumors harbor both CTNNB1 and TERT promoter mutations may represent a molecular subtype that is particularly dependent on MAPK/ERK signaling, and therefore potentially responsive to therapies that target this cascade. Genomic testing for the co-occurrence of these two mutations could, in principle, help identify patients most likely to benefit from such an approach, although the researchers emphasize that their work is preclinical and that translating the findings into patient treatment will require further study.

Beyond its therapeutic implications, the study fills an important conceptual void in liver cancer biology. β-catenin is classically understood as a transcriptional co-activator in the Wnt signaling pathway, and TERT as a guardian of chromosome integrity, so the demonstration that their cooperation routes through MAPK/ERK activation reveals an unexpected layer of crosstalk between these canonical systems. The work was supported by grants from the National Research Foundation of Korea and approved by the Animal Policy and Welfare Committee of Kyung Hee University. As sequencing of liver tumors becomes increasingly routine in clinical practice, mechanistic studies like this one, which connect specific mutation combinations to druggable signaling dependencies, will become ever more essential to realizing the promise of precision oncology in hepatocellular carcinoma.

Subject of Research: Cooperation between TERT promoter mutations and β-catenin activation in hepatocellular carcinoma development via MAPK/ERK signaling

Article Title: Telomerase reverse transcriptase (TERT) accelerates β-catenin-driven hepatocarcinogenesis via MAPK/ERK pathway activation

Article References: Park, H., Lee, J., Moon, H., & Ro, S. W. (2026). Telomerase reverse transcriptase (TERT) accelerates β-catenin-driven hepatocarcinogenesis via MAPK/ERK pathway activation. Cancer Cell International. https://doi.org/10.1186/s12935-026-04329-9

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04329-9

Keywords: TERT promoter, β-catenin, hepatocellular carcinoma, MAPK/ERK pathway, liver cancer, telomerase, CTNNB1, oncogenic synergy, hydrodynamic tail vein injection, ERK1/2 phosphorylation, MEK1/2, cancer genetics